Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Net Cash Flow came in at -$49.9 million in Q2 2026, up 31.92% YoY from -$37.8 million in Q2 2025, and up 25.15% on a QoQ basis from -$66.7 million in Q1 2026.
Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Net Cash Flow data on file, last reported at -$49.9 million in Q2 2026.
- Quarterly Net Cash Flow rose 31.92% year-over-year to -$49.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$208.4 million (up 13.91% YoY) and the FY2025 annual result came in at -$252.2 million, down 171.27% from the prior year.
- Net Cash Flow advanced to -$49.9 million in Q2 2026, from -$66.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $504.6 million in Q2 2024 to a low of -$87.0 million in Q1 2025.
- A 5-year average of $4.1 million and a median of -$39.5 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1200.46% — and 2023, when it surged 2780.59%.
- Tracing BCYC's Net Cash Flow over 5 years: stood at -$25.9 million in 2022, then slumped by 81.5% to -$47.0 million in 2023, then surged by 79.64% to -$9.6 million in 2024, then plunged by 108.5% to -$19.9 million in 2025, then slumped by 150.42% to -$49.9 million in 2026.
- The last three Net Cash Flow figures came in at -$49.9 million (Q2 2026), -$66.7 million (Q1 2026), and -$19.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -49.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.92 Mn |
| Jun 30, 2026 | -49.92 Mn |
| Mar 31, 2026 | -66.69 Mn |
| Mar 31, 2026 | -66.69 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Sep 30, 2025 | -71.88 Mn |
| Sep 30, 2025 | -71.88 Mn |
| Jun 30, 2025 | -73.33 Mn |
| Jun 30, 2025 | -73.33 Mn |
| Mar 31, 2025 | -87.02 Mn |
| Mar 31, 2025 | -87.02 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Sep 30, 2024 | -72.20 Mn |
| Sep 30, 2024 | -72.20 Mn |
| Jun 30, 2024 | 504.56 Mn |
| Jun 30, 2024 | 504.56 Mn |
| Mar 31, 2024 | -69.01 Mn |
| Mar 31, 2024 | -69.01 Mn |